Intrathecal Baclofen for the Treatment of Dystonia in Patients with Reflex Sympathetic Dystrophy
Top Cited Papers
Open Access
- 31 August 2000
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (9), 625-630
- https://doi.org/10.1056/nejm200008313430905
Abstract
Patients with reflex sympathetic dystrophy (also known as the complex regional pain syndrome) may have dystonia, which is often unresponsive to treatment. Some forms of dystonia respond to the intrathecal administration of baclofen, a specific γ-aminobutyric acid–receptor (type B) agonist that inhibits sensory input to the neurons of the spinal cord. We evaluated this treatment in seven women who had reflex sympathetic dystrophy with multifocal or generalized tonic dystonia.Keywords
This publication has 25 references indexed in Scilit:
- GABA and its receptors in the spinal cordTrends in Pharmacological Sciences, 1996
- Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticityJournal of Neurosurgery, 1996
- The reflex sympathetic dystrophy syndromeInternational Journal of Rehabilitation Research, 1995
- Intrathecal baclofen for motor disordersMovement Disorders, 1995
- Causalgia—reflex sympathetic dystrophy—sympathetically maintained pain: Myth and realityMuscle & Nerve, 1993
- Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patientsThe Lancet, 1993
- The causalgia—dystonia syndromeBrain, 1993
- Presynaptic inhibition of muscle spindle and tendon organ afferents in the mammalian spinal cordTrends in Neurosciences, 1990
- Intrathecal Baclofen for Severe Spinal SpasticityNew England Journal of Medicine, 1989
- Effect of some centrally administered putative amino acid neurotransmitters on carrageenan-induced paw oedema in ratsJournal of Pharmacy and Pharmacology, 1986